SNDL (NASDAQ:SNDL – Get Free Report) and ImmuCell (NASDAQ:ICCC – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, analyst recommendations, institutional ownership, profitability and dividends.
Analyst Ratings
This is a summary of current recommendations and price targets for SNDL and ImmuCell, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| SNDL | 0 | 0 | 1 | 0 | 3.00 |
| ImmuCell | 0 | 0 | 0 | 0 | 0.00 |
SNDL presently has a consensus target price of $4.50, indicating a potential upside of 75.78%. Given SNDL’s stronger consensus rating and higher probable upside, equities analysts clearly believe SNDL is more favorable than ImmuCell.
Volatility and Risk
Institutional & Insider Ownership
13.5% of ImmuCell shares are owned by institutional investors. 5.6% of ImmuCell shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares SNDL and ImmuCell”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| SNDL | $671.81 million | 1.00 | -$69.18 million | ($0.27) | -9.48 |
| ImmuCell | $26.49 million | 1.93 | -$2.16 million | $0.19 | 29.79 |
ImmuCell has lower revenue, but higher earnings than SNDL. SNDL is trading at a lower price-to-earnings ratio than ImmuCell, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares SNDL and ImmuCell’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| SNDL | -10.38% | -8.58% | -7.23% |
| ImmuCell | 6.23% | 6.25% | 3.87% |
Summary
ImmuCell beats SNDL on 9 of the 14 factors compared between the two stocks.
About SNDL
SNDL Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments segments. It engages in the cultivation, distribution, and sale of cannabis for the adult-use and medical markets; sells wines, beers, and spirits through wholly owned liquor stores; and private sale of recreational cannabis through wholly owned and franchised retail cannabis stores. In addition, the company produces and distributes inhalable products, such as flower, pre-rolls, and vapes. It offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. The company was formerly known as Sundial Growers Inc. and changed its name to SNDL Inc. in July 2022. SNDL Inc. was incorporated in 2006 and is headquartered in Calgary, Canada.
About ImmuCell
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
Receive News & Ratings for SNDL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SNDL and related companies with MarketBeat.com's FREE daily email newsletter.
